Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands - Focus on reproductive system

被引:14
作者
Arvat, E
Gianotti, L
Giordano, R
Broglio, F
Maccario, M
Lanfranco, F
Muccioli, G
Papotti, M
Graziani, A
Ghigo, E
Deghenghi, R
机构
[1] Univ Turin, Dept Internal Med, Div Endocrinol, I-10126 Turin, Italy
[2] Univ Turin, Dept Pharmacol, I-10126 Turin, Italy
[3] Univ Turin, Dept Biomed Sci, I-10126 Turin, Italy
[4] Univ Turin, Dept Genet & Biochem, I-10126 Turin, Italy
[5] Europeptide, Argenteuil, France
关键词
growth hormone-releasing hormone; growth hormone secretagogues; prolactin; adenocorticotropic hormone; cortisol; central nervous system;
D O I
10.1385/ENDO:14:1:035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Growth hormone-releasing hormone (GHRH) and somatostatin are the most important hypothalamic neurohormones controlling growth hormone (CH) secretion. Several neurotransmitters and neuropeptides also play an important role in the control of GH secretion, mainly acting via modulation of GHRH and somatostatin. In the past two decades, particular attention has been given to a new family of substances showing a strong GH-releasing effect: GH secretagogues (GHSs), GHSs increase GH secretion in a dose- and age-related manner after iv and even oral administration. The endocrine effects of GHSs, are not fully specific for GH; they show, in fact, prolactin-(PRL), adenocorticotropic hormone- and cortisol-releasing effects. Specific GHS receptors are present in both the central nervous system and peripheral tissues, where they mediate several extraendocrine effects of GHSs, The isolation of these "orphan" receptors suggested the existence of an endogenous GHS-like ligand that could be represented by a recently discovered gastric peptide, named ghrelin. The interaction between GHSs and GHRH at the central level and in the pituitary gland, but not at peripheral level, has clearly been shown, Because GHRH and GHS receptors share the same localization in some peripheral tissues, they may have some interactions even at this level.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 135 条
[1]   SOMATOSTATIN ACTION ON RAT OVARIAN STEROIDOGENESIS [J].
ANDREANI, CL ;
LAZZARIN, N ;
PIERRO, E ;
LANZONE, A ;
MANCUSO, S .
HUMAN REPRODUCTION, 1995, 10 (08) :1968-1973
[2]   Growth hormone cotreatment with gonadotropins in ovulation induction [J].
Artini, PG ;
deMicheroux, AA ;
DAmbrogio, G .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1996, 19 (11) :763-779
[3]   ARGININE AND GROWTH HORMONE-RELEASING HORMONE RESTORE THE BLUNTED GROWTH HORMONE-RELEASING ACTIVITY OF HEXARELIN IN ELDERLY SUBJECTS [J].
ARVAT, E ;
GIANOTTI, L ;
GROTTOLI, S ;
IMBIMBO, BP ;
LENAERTS, V ;
DEGHENGHI, R ;
CAMANNI, F ;
GHIGO, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (05) :1440-1443
[4]   Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of hexarelin and GHRP-2 in humans [J].
Arvat, E ;
Di Vito, L ;
Lanfranco, F ;
Broglio, F ;
Giordano, R ;
Benso, A ;
Muccioli, GP ;
Deghenghi, R ;
Ghigo, E .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (02) :91-97
[5]   Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man [J].
Arvat, E ;
DiVito, L ;
Gianotti, L ;
Ramunni, J ;
Boghen, MF ;
Deghenghi, R ;
Camanni, F ;
Ghigo, E .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (01) :83-88
[6]   Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans [J].
Arvat, E ;
Maccagno, B ;
Ramunni, J ;
DiVito, L ;
Broglio, F ;
Deghenghi, R ;
Camanni, F ;
Ghigo, E .
NEUROENDOCRINOLOGY, 1997, 66 (06) :432-438
[7]   The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations [J].
Arvat, E ;
Ramunni, J ;
Bellone, J ;
Di Vito, L ;
Baffoni, C ;
Broglio, F ;
Deghenghi, R ;
Bartolotta, E ;
Ghigo, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 137 (06) :635-642
[8]   Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease [J].
Arvat, E ;
Ramunni, J ;
Maccagno, B ;
Giordano, R ;
Broglio, F ;
Deghenghi, R ;
Boscaro, M ;
Ghigo, E .
NEUROENDOCRINOLOGY, 1999, 70 (03) :200-206
[9]   Age-related Variations in the Neuroendocrine Control, More Than Impaired Receptor Sensitivity, Cause the Reduction in the GH-releasing Activity of GHRPs in Human Aging [J].
Arvat E. ;
Ceda G. ;
Di Vito L. ;
Ramunni J. ;
Gianotti L. ;
Broglio F. ;
Deghenghi R. ;
Ghigo E. .
Pituitary, 1998, 1 (1) :51-58
[10]   Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women [J].
Arvat, E ;
Gianotti, L ;
Broglio, F ;
Maccagno, B ;
Bertagna, A ;
Deghenghi, R ;
Camanni, F ;
Ghigo, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 136 (05) :483-487